Pharmafile Logo

Event: World Pharma Pricing and Market Access Congress

May 2, 2019 | Pharma, healthcare 

Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.

This two-day event was attended by over 600 delegates, including a number of payers from Europe, the US and Latin America, plus representatives from the industry and other market access organizations. In the morning plenary sessions, we heard a range of perspectives on value, demonstrating that “value is in the eye of the beholder”. A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding pipeline of Advanced Therapy Medicinal Products (ATMPs) such as cell and gene therapy. There was much discussion about how these products, with their high upfront costs and inherent limitations will necessitate the creation of a new access model. To allow negotiations to move forward and ensure more timely access to patients, we need to look at using innovative payment models such as outcomes-based contracting and find ways of addressing uncertainty.

Find out more about their time at the event.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.